ECONOMIC VALUE OF RSV MATERNAL VACCINATION TO PREVENT INFANT DISEASE IN ECUADOR
Author(s)
RAFAEL BOLAÑOS-DIAZ, PhD1, RICARDO YAJAMIN, MSc2, Xavier Sanchez, MSc, PhD, MD3, Ruth Jimbo Sotomayor, MD4.
1Pfizer, Lima, Peru, 2Value Health Economics Group, QUITO, Ecuador, 3Pontificia Universidad Católica del Ecuador, Quito, Ecuador, 4Pontificia Universidad Catouca Del Ecuador, Quito, Ecuador.
1Pfizer, Lima, Peru, 2Value Health Economics Group, QUITO, Ecuador, 3Pontificia Universidad Católica del Ecuador, Quito, Ecuador, 4Pontificia Universidad Catouca Del Ecuador, Quito, Ecuador.
OBJECTIVES: This study aimed to estimate the cost-utility of RSVpreF maternal vaccination for preventing RSV-related illness in Ecuadorian infants.
METHODS: We developed a population-based Markov model to compare maternal RSVpreF vaccination (MV) against no vaccination for 1 annual birth cohort. Clinical outcomes, including morbidity and mortality, and direct medical costs were evaluated over a 12-month analytic horizon and extrapolated to 99 years from the Ecuadorian health system perspective. A 5% annual discount rate was applied to both costs and outcomes. The model included mutually exclusive health states: healthy, infected (comprising outpatient care and hospitalization), and an absorbing state of death. Epidemiological and cost parameters were derived from the National Institute of Statistics and Censuses, the Ecuadorian Institute of Social Security, the Pan-American Health Organization, and peer-reviewed literature. Key assumptions included a vaccine uptake of 50% and the use of a conservative correction factor for case underreporting (1.32). The cost-effectiveness threshold was based on Ecuadorian 3xGDP per capita (USD 20,818). Deterministic and probabilistic sensitivity analyses were conducted to evaluate the robustness of the findings.
RESULTS: A total of 215,714 infants were modelled. Without intervention, over 16,880 RSV cases were estimated (43% emergency department care encounters [ED], 42% outpatient clinic encounters [OC], and 15% hospitalizations). MV led to avert 671 hospitalizations, 1,342 ED, 1,328 OC and 6 deaths, which translated into a 3 million USD decrease of direct medical costs. The incremental cost-effectiveness ratio was estimated at USD 19,380 per QALY gained, indicating that MV is cost-effective for the Ecuadorian health system. Parameters such as the incidence of RSV hospitalizations and the effectiveness of the RSVpreF vaccination were identified as model drivers.
CONCLUSIONS: Maternal RSVpreF vaccination represents a cost-effective strategy for Ecuador. Integrating this intervention into the national immunization schedule could substantially reduce RSV-related morbidity, hospitalizations, and associated healthcare expenditures, ultimately improving infant health outcomes.
METHODS: We developed a population-based Markov model to compare maternal RSVpreF vaccination (MV) against no vaccination for 1 annual birth cohort. Clinical outcomes, including morbidity and mortality, and direct medical costs were evaluated over a 12-month analytic horizon and extrapolated to 99 years from the Ecuadorian health system perspective. A 5% annual discount rate was applied to both costs and outcomes. The model included mutually exclusive health states: healthy, infected (comprising outpatient care and hospitalization), and an absorbing state of death. Epidemiological and cost parameters were derived from the National Institute of Statistics and Censuses, the Ecuadorian Institute of Social Security, the Pan-American Health Organization, and peer-reviewed literature. Key assumptions included a vaccine uptake of 50% and the use of a conservative correction factor for case underreporting (1.32). The cost-effectiveness threshold was based on Ecuadorian 3xGDP per capita (USD 20,818). Deterministic and probabilistic sensitivity analyses were conducted to evaluate the robustness of the findings.
RESULTS: A total of 215,714 infants were modelled. Without intervention, over 16,880 RSV cases were estimated (43% emergency department care encounters [ED], 42% outpatient clinic encounters [OC], and 15% hospitalizations). MV led to avert 671 hospitalizations, 1,342 ED, 1,328 OC and 6 deaths, which translated into a 3 million USD decrease of direct medical costs. The incremental cost-effectiveness ratio was estimated at USD 19,380 per QALY gained, indicating that MV is cost-effective for the Ecuadorian health system. Parameters such as the incidence of RSV hospitalizations and the effectiveness of the RSVpreF vaccination were identified as model drivers.
CONCLUSIONS: Maternal RSVpreF vaccination represents a cost-effective strategy for Ecuador. Integrating this intervention into the national immunization schedule could substantially reduce RSV-related morbidity, hospitalizations, and associated healthcare expenditures, ultimately improving infant health outcomes.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE409
Topic
Economic Evaluation
Disease
STA: Vaccines